Takeda Pharmaceutical Company Limited (4502)
Takeda Pharmaceutical (4502 JP) - 26/3 Q1 results: Weak US market(Buy)
TAK-861: Rival drug meets primary endpoint in Phase 2 trial(Buy)
Two successful phase III trials for narcolepsy type 1 drug(Buy)